MCF-7 Cells

• 

  Subject Areas on Research

  • A Single-Cell Assay for Time Lapse Studies of Exosome Secretion and Cell Behaviors. 
  • A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest. 
  • A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome. 
  • A role for myocilin in receptor-mediated endocytosis. 
  • A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. 
  • ATM functions at the peroxisome to induce pexophagy in response to ROS. 
  • Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. 
  • An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles. 
  • An array of 60,000 antibodies for proteome-scale antibody generation and target discovery. 
  • An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. 
  • Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer. 
  • Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. 
  • Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells-in vitro and ex vivo study. 
  • Chemical Denaturation and Protein Precipitation Approach for Discovery and Quantitation of Protein-Drug Interactions. 
  • Chemo-Selection Strategy for Limited Proteolysis Experiments on the Proteomic Scale. 
  • Chemotaxis-driven assembly of endothelial barrier in a tumor-on-a-chip platform. 
  • Comparative Analysis of Protein Folding Stability-Based Profiling Methods for Characterization of Biological Phenotypes. 
  • Comprehensive profiling of amino acid response uncovers unique methionine-deprived response dependent on intact creatine biosynthesis. 
  • DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. 
  • Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. 
  • Differential recruitment of co-regulatory proteins to the human estrogen receptor 1 in response to xenoestrogens. 
  • Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. 
  • Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. 
  • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. 
  • Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements. 
  • Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D Microarrays. 
  • Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer. 
  • Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. 
  • Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. 
  • Effect of molecular characteristics on cellular uptake, subcellular localization, and phototoxicity of Zn(II) N-alkylpyridylporphyrins. 
  • Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. 
  • Erythropoietin Stimulates Tumor Growth via EphB4. 
  • Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. 
  • Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. 
  • Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis. 
  • Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). 
  • Foxo-dependent Par-4 Upregulation Prevents Long-term Survival of Residual Cells Following PI3K-Akt Inhibition. 
  • Heat Shock Protein 70 (Hsp70) Suppresses RIP1-Dependent Apoptotic and Necroptotic Cascades. 
  • Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. 
  • HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis. 
  • IKKβ promotes metabolic adaptation to glutamine deprivation via phosphorylation and inhibition of PFKFB3. 
  • In Situ Proapoptotic Peptide-Generating Rapeseed Protein-Based Nanocomplexes Synergize Chemotherapy for Cathepsin-B Overexpressing Breast Cancer. 
  • Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. 
  • JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. 
  • Large-Scale Analysis of Breast Cancer-Related Conformational Changes in Proteins Using Limited Proteolysis. 
  • Large-Scale Analysis of Breast Cancer-Related Conformational Changes in Proteins Using SILAC-SPROX. 
  • Light uncages a copper complex to induce nonapoptotic cell death. 
  • Limitations of an ex vivo breast cancer model for studying the mechanism of action of the anticancer drug paclitaxel. 
  • Lipid droplet velocity is a microenvironmental sensor of aggressive tumors regulated by V-ATPase and PEDF. 
  • MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. 
  • Mass Spectrometry-Based Proteomics for Analysis of Hydrophilic Phosphopeptides. 
  • Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells. 
  • Nuclear deformation during breast cancer cell transmigration. 
  • Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. 
  • Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. 
  • Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. 
  • Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. 
  • Post-illumination cellular effects of photodynamic treatment. 
  • Proteome-Wide Characterization of Phosphorylation-Induced Conformational Changes in Breast Cancer. 
  • Quantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor Density. 
  • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. 
  • Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding. 
  • Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. 
  • Sensitive and quantitative probing of pseudouridine modification in mRNA and long noncoding RNA. 
  • Serine synthesis through PHGDH coordinates nucleotide levels by maintaining central carbon metabolism. 
  • Shear Modulus Measurement by Quantitative Phase Imaging and Correlation with Atomic Force Microscopy. 
  • Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. 
  • Subglutinol A, an immunosuppressive α-pyrone diterpenoid from Fusarium subglutinans, acts as an estrogen receptor antagonist. 
  • TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death. 
  • Tandem Mass Tag Labeling Facilitates Reversed-Phase Liquid Chromatography-Mass Spectrometry Analysis of Hydrophilic Phosphopeptides. 
  • The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. 
  • The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2. 
  • The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. 
  • Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. 
  • Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology